First Line Metastatic Pancreatic Cancer : 5FU/LV+Nal-IRI, Gemcitabine+Nab-paclitaxel or a Sequential Regimen of 2 Months 5FU/LV+Nal-IRI

Clinical trial NCT03693677 · COMPLETED

Trial details

NCT number: NCT03693677
Sponsor: Federation Francophone de Cancerologie Digestive
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Metastatic Pancreatic Cancer

Start date: 2018-11-16
Primary completion: 2025-01-10
Enrollment: 288

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.